Company to deliver three oral and three poster
presentations highlighting its portfolio of non-viral genetic
medicines
Presentations to include new pre-clinical data
on lead non-viral candidates P-KLKB1-101 and P-FVIII-101
SAN
DIEGO, April 18, 2024 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell therapy
and genetic medicines company advancing a new class of treatments
for patients with cancer and rare diseases, today announced that
six data presentations highlighting the Company's preclinical gene
therapy programs and platforms will be presented at the American
Society of Gene and Cell Therapy (ASGCT) 27th Annual
Meeting, being held in Baltimore,
MD and virtually on May 7-11,
2024.
Following the Company's recent R&D Day held on April 17, 2024, Poseida is focused on advancing
fully non-viral genetic medicines employing differentiated gene
delivery, editing and insertion technology in addition to its
ongoing non-viral allogeneic CAR T programs. The Company's
presentations at ASGCT will feature data on its lead genetic
medicine programs P-KLKB1-101 for Hereditary Angioedema (HAE) (gene
editing), and P-FVIII-101 for Hemophilia A (non-viral, whole gene
insertion).
Oral Presentations:
Title: Highly Specific Non-Viral Gene Editing with
P-KLKB1-101 for Hereditary Angioedema
Presenting
Author: Blair Madison, Ph.D.,
Poseida Therapeutics
Session Title: Correction of Genetic Disorders of the Blood
and Immune System
Presentation Date/Time: Thursday May
9, 2024, 1:30 - 1:45 PM ET
Location: Room 314-317
Abstract Number: 170
Title: Sustained FVIII Expression with a Tolerable,
Titratable, Fully Non-Viral Gene Therapy for Hemophilia A
Presenting Author: Brian
Truong, Ph.D., Poseida Therapeutics
Session Title: Liver Genetic Diseases
Presentation Date/Time: Thursday May
9, 2024, 5:00 - 5:15 PM ET
Location: Room 324-326
Abstract Number: 210
Title: A Durable Gene Therapy with a Robust AAV-LNP
Delivery System Allowing for a Reduced AAV
Dose
Presenting Author: Jack
Rychak, Ph.D., Poseida Therapeutics
Session Title: AAV Vectors - Preclinical and
Proof-of-Concept: Technology Focus
Presentation Date/Time: Friday May
10, 2024, 1:45 - 2:00 PM
ET
Location: Ballroom 2
Abstract Number: 248
Poster Presentations:
Title: Advanced Gene Editing with an Enhanced
Site-Specific Nuclease for Knock-Out and Knock-In
Applications
Presenting Author: Oscar Alvarez, Ph.D., Poseida Therapeutics
Session Title: Wednesday Posters: Gene Targeting and Gene
Correction New Technologies
Session Date/Time: Wednesday, May 8,
2024, 12:00 PM ET
Location: Exhibit Hall
Abstract Number: 717
Title: Optimizing Lipid Nanoparticle Formulations
for Enhanced Non-Viral Gene Therapy: Overcoming DNA Delivery
Challenges and Achieving High-Efficiency Transgene
Integration
Presenting Author: George
Wang, Ph.D., Poseida Therapeutics
Session Title: Thursday Posters: Other Nonviral Delivery
Session Date/Time: Thursday, May 9,
2024, 12:00 PM ET
Location: Exhibit Hall
Abstract Number: 1239
Title: Novel Biodegradable Lipid Nanoparticles (LNP)
for Co-Encapsulation of Complex Nucleic Acid Payloads for In Vivo
Genome Editing
Presenting Author: Alicia
Davis, Ph.D., Poseida Therapeutics
Session Title: Friday Posters: Other Nonviral Delivery
Session Date/Time: Friday, May 10,
2024, 12:00 PM ET
Location: Exhibit Hall
Abstract Number: 1737
Accepted abstracts will be available on the ASGCT Annual
Meeting website on April 22,
2024 at 4:30 PM ET.
Presentations will be available on the Scientific
Publications page of Poseida's website on Friday, May 10, 2024 at 6:00 AM ET.
About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical
company advancing differentiated cell therapies and genetic
medicines with the capacity to cure certain cancers and rare
diseases. The Company's pipeline includes investigational
allogeneic CAR-T cell therapies for both solid tumors and
hematologic cancers as well as investigational in vivo genetic
medicines that address patient populations with high unmet medical
need. The Company's approach is based on its proprietary genetic
editing platforms, including its non-viral piggyBac® DNA
Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System,
Booster Molecule and nanoparticle gene delivery technologies, as
well as in-house GMP cell therapy manufacturing. The Company has
formed a global strategic collaboration with Roche to unlock the
promise of cell therapies for patients with hematologic
malignancies. Learn more at www.poseida.com and connect with
Poseida on X and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, expected plans with respect to
clinical trials, including timing of regulatory submissions and
approvals and clinical data updates; anticipated timelines and
milestones with respect to the Company's development programs and
manufacturing activities and capabilities; the potential
capabilities and benefits of the Company's technology platforms and
product candidates, including the tolerability and efficacy and
safety profile of such product candidates; and the Company's plans
and strategy with respect to developing its technologies and
product candidates. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. These
forward-looking statements are based upon the Company's current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without
limitation, the Company's reliance on third parties for various
aspects of its business; risks and uncertainties associated with
development and regulatory approval of novel product candidates in
the biopharmaceutical industry; the Company's ability to retain key
scientific or management personnel; and the other risks described
in the Company's filings with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. The
Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-strong-lineup-of-presentations-at-the-american-society-of-gene-and-cell-therapy-27th-annual-meeting-302120305.html
SOURCE Poseida Therapeutics, Inc.
